Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTEGRATE adaptive platform trial in hospitalized patients with Lassa fever
PACTR202312770983740Phase 2Not yet recruiting
- Sponsor
- Irrua Specialist Teaching Hospital
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of ribavirin, favipiravir and dexamethasone in Lassa fever (4 arms), sponsored by Irrua Specialist Teaching Hospital. Primary endpoint: Primary composite endpoint. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
ribavirinfavipiravirdexamethasone
03
Conditions
Lassa fever
Beyond the preview
Go deeper on PACTR202312770983740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202312770983740.